retatrutide clinical trials efficacy (RETA) is one of the most promising investigational peptides in obesity research— Lilly's triple agonist, retatrutide, delivered

This head-to-head randomized trial directly compared tirzepatide with semaglutide for obesity treatment and provides high-level evidence for the magnitude of weight loss achievable with current incretin-based pharmacotherapy

Fits easily into medication management workflow

President Trump announced a new deal this week with drugmakers Eli Lilly and Novo Nordisk, aimed at expanding coverage and lowering prices for GLP-1 medications

Older stimulant medications can also elevate heart rate and blood pressure, posing cardiovascular risks for susceptible individuals

Each step in that titration demands a different volume draw from the syringe

A provider may prescribe a compounded medication for several reasons, allowing for a more individualized treatment plan